Drug intelligence / Profile preview

FTL-008.16

Development stage: Phase 1
Lead developer: SOUND Biopharmaceuticals
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

FTL-008.16 is a bispecific antibody developed by Sound Biopharmaceuticals that targets both 4-1BBL (tumor necrosis factor ligand superfamily member 9) and 5T4 (trophoblast glycoprotein). Its mechanism of action involves modulation of these two targets, which are implicated in immune activation and tumor cell recognition, respectively. The drug is being investigated for the treatment of advanced or metastatic solid tumors, with its highest development phase currently at Phase 1 clinical trials[1][2][3][4][5]. The agent is administered intravenously.

Targets

TNFSF9 (4-1BB ligand)TPBG (Trophoblast glycoprotein)

Beyond the preview

Go deeper on FTL-008.16.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FTL-008.16.

Explore the full profile